hero image

Biogen Idec to Present at the 26th Annual JPMorgan Healthcare Conference

January 3, 2008 Investor Relations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ:BIIB) announced today that its presentation and breakout session at the 26th Annual JPMorgan Healthcare Conference will be webcast live via the internet, on Monday, January 7, 2008 at 4:00 p.m. PT (7:00 p.m. ET). To access the live webcast, please visit Biogen Idec’s homepage, www.biogenidec.com. An archived version of the webcast will be available for two weeks following the presentation.

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com.

 

Contact:

Biogen Idec
Heidi Brewster, 617-679-2757
Investor Relations

thumb
June 22, 2022
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

Biogen is collaborating with Happify Health to support people living with Multiple Sclerosis (MS) Happify Health’s platform supports the MS patient care journey, keeps patients abreast of treatment advances, helps support medication adherence, promotes holistic wellness goals, connects users with

thumb
June 21, 2022
European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

Patent covers approved dosing regimen for TECFIDERA and expires in 2028 CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office has granted a patent that expires in February 2028 related to TECFIDERA ® (dimethyl fumarate).